A comprehensive analysis of mutational signatures of a large number of gliomas revealed that TMZ-sensitive tumors frequently acquire TMZ resistance due to MMR defects, which is associated with poor patient survival (and low response to immunotherapy) [160]. This evidence concerns the gene MRC1 and glioma.